Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S4370-4371: 2)
This bill reauthorizes parts of the Kay Hagan Tick Act by amending two sections of the Public Health Service Act that support a national strategy and regional centers for vector-borne disease and enhanced support for state and local health departments. It adds an explicit reference to coordination with the Tick-Borne Disease Working Group and other appropriate individuals.
Progressives emphasize that reduced authorized funding risks undermining surveillance, research, and equity; conservatives view the reduced funding as a fiscal positive.
Relative to its intended legislative type, this bill is a narrowly focused administrative/operational reauthorization that explicitly amends statute citations and funding authorizations for existing vector-borne disease programs.
This bill reauthorizes parts of the Kay Hagan Tick Act by amending two sections of the Public Health Service Act that support a national strategy and regional centers for vector-borne disease and enhanced support for state and local health departments.
It adds an explicit reference to coordination with the Tick-Borne Disease Working Group and other appropriate individuals.
The bill sets authorized funding levels for these programs for fiscal years 2026 through 2030: $8,000,000 per year for the national strategy/centers provision (replacing a prior $10,000,000 level for 2021–2025) and $19,000,000 per year for enhanced support to health departments (replacing a prior $20,000,000 level for 2021–2025).
On content alone, this is a short, technical reauthorization of existing public health programs with modest funding and little ideological load, which makes it more likely than not to be enacted. The principal barriers are procedural (scheduling, floor time, or political objections to any new authorizations) and the fact that authorization does not guarantee appropriation.
Relative to its intended legislative type, this bill is a narrowly focused administrative/operational reauthorization that explicitly amends statute citations and funding authorizations for existing vector-borne disease programs. It supplies concrete dollar authorizations and statutory targets but adds little in the way of implementation sequencing, appropriation language, oversight, or new accountability provisions.
Progressives emphasize that reduced authorized funding risks undermining surveillance, research, and equity; conservatives view the reduced funding as a fiscal positive.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize that reduced authorized funding risks undermining surveillance, research, and equity; conservatives view the reduced funding as a fiscal positive.
A mainstream progressive would welcome the reauthorization because it continues federal support for tick-borne and other vector-borne disease work, which aligns with public-health, environmental, and equity priorities.
However, they would be concerned that the bill reduces annual authorized funding compared with the prior authorization period, which may undermine surveillance, research, and service delivery—especially as climate change expands vector ranges.
They would likely view the added coordination language with the Tick-Borne Disease Working Group positively but see the overall package as an underfunded continuation rather than a strengthened response.
A pragmatic moderate would view the bill as a sensible, low-conflict reauthorization that keeps useful public-health programs operating while trimming authorized spending modestly.
They would appreciate continuity for surveillance and state support and the explicit coordination with the Tick-Borne Disease Working Group, but would want clearer accountability, measurable outcomes, and assurance that the modest cuts do not erode core capabilities.
Overall they would likely support it if paired with oversight and reporting requirements in appropriations or committee guidance.
A mainstream conservative would generally be favorable to reauthorizing these public-health programs because they support disease surveillance and protect public safety, and would welcome the modest reduction in authorized spending.
They would view the bill as a restrained federal role that continues essential functions while trimming costs.
Their remaining concerns would focus on ensuring efficiency, minimizing federal overreach, and preserving state flexibility in implementation.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, this is a short, technical reauthorization of existing public health programs with modest funding and little ideological load, which makes it more likely than not to be enacted. The principal barriers are procedural (scheduling, floor time, or political objections to any new authorizations) and the fact that authorization does not guarantee appropriation.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize that reduced authorized funding risks undermining surveillance, research, and equity; conservatives view the reduced…
On content alone, this is a short, technical reauthorization of existing public health programs with modest funding and little ideological…
Relative to its intended legislative type, this bill is a narrowly focused administrative/operational reauthorization that explicitly amends statute citations and funding authorizations for existing vector-borne disease…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.